XARACOLL Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Xaracoll patents expire, and when can generic versions of Xaracoll launch?
Xaracoll is a drug marketed by Innocoll Pharms and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-six patent family members in fifteen countries.
The generic ingredient in XARACOLL is bupivacaine hydrochloride. There are twelve drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xaracoll
A generic version of XARACOLL was approved as bupivacaine hydrochloride by HOSPIRA on February 17th, 1986.
Summary for XARACOLL
| International Patents: | 26 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 123 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,320 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in XARACOLL? | XARACOLL excipients list |
| DailyMed Link: | XARACOLL at DailyMed |
Recent Clinical Trials for XARACOLL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Premier Research Group plc | Phase 3 |
| Cmed | Phase 3 |
| Innocoll | Phase 3 |
Pharmacology for XARACOLL
| Drug Class | Amide Local Anesthetic |
| Physiological Effect | Local Anesthesia |
Anatomical Therapeutic Chemical (ATC) Classes for XARACOLL
US Patents and Regulatory Information for XARACOLL
XARACOLL is protected by one US patents and one FDA Regulatory Exclusivity.
Patents protecting XARACOLL
Drug delivery device for providing local analgesia, local anesthesia or nerve blockage
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION
FDA Regulatory Exclusivity protecting XARACOLL
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innocoll Pharms | XARACOLL | bupivacaine hydrochloride | IMPLANT;IMPLANTATION | 209511-001 | Aug 28, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Innocoll Pharms | XARACOLL | bupivacaine hydrochloride | IMPLANT;IMPLANTATION | 209511-001 | Aug 28, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XARACOLL
See the table below for patents covering XARACOLL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ireland | 20070220 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | ⤷ Try a Trial |
| Spain | 2582368 | ⤷ Try a Trial | |
| Germany | 202008018583 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
DrugChatter - AI-based answers to questions about drugs
RxJam - Trigger-based marketing for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
